PROVIDENCE, R.I., March 7, 2024 /PRNewswire/ — Next generation genomic tools company, Nabsys®, has executed a nonexclusive agreement with Canadian distributor, DMark Biosciences (“DMark”), for sales of its OhmX™ platform. OhmX is Nabsys’ first commercially available product and was released in October 2023.
DMark will be responsible for distributing both the Nabsys OhmX™ Analyzer and consumables into both public and private research core labs and institutions in the Canadian market.
The OhmX Analyzer utilizes electronic genome mapping (EGM), a novel technology that leverages state of the art electronic nanodetectors to detect tagged high molecular weight DNA molecules with unprecedented precision and speed offering a superior and reliable tool for structural variant analysis.
OhmX has a small benchtop footprint and can fit easily into most laboratories. The instrument comes with access to a cloud-based secondary analytics software called Human Chromosome Explorer™ (HCE). HCE was developed by Hitachi High-Tech America, Inc. and is now offered as a standalone analytical suite for OhmX data to enable structural variant calling and reporting.
“With growing demand for the OhmX platform in the US, this distribution agreement marks an important step towards establishing a strong global distribution network,” Nabsys’ Chief Commercial Officer, Justin Bingham, remarked. “We look forward to a successful collaboration with DMark and the expanded use of electronic genome mapping for enhanced SV analysis across a broader geography of North America.”
“DMark’s approach to understanding the gaps in genomics technology to enable cutting-edge research to be performed faster, more accurately, and at a lower cost aligns perfectly to Nabsys’ mission. Together, we will enable a broad range of applications – from rare disease and cancer to cell and gene therapy – to advance our customers’ research,” said DMark CEO, Duane Mendis, Ph.D.
Contact Information
Elise Benson
Director of Marketing
Nabsys
benson@nabsys.com
About Nabsys 2.0, LLC
The Nabsys 2.0, LLC (“Nabsys”) mission is to advance the understanding of disease, increase diagnostic yield, and improve patient outcomes by enabling routine, accurate, cost-effective analysis of genomic structural variation. Located in Providence, RI, Nabsys employs a growing interdisciplinary group of dedicated scientists, engineers, and other professionals committed to the advancement of genomic analysis.
About DMark Biosciences
DMark Biosciences Inc. stands as a forefront Genomics Solutions powerhouse in Canada since 2008. The company is dedicated to fostering a deeper understanding of biosciences through genomic and multiomic workflows. With a recent ISO 9001:2015 certification, DMark is committed to delivering cutting-edge solutions, serving as a reliable source for the latest developments, breakthroughs, and trends within the biotech sector.
SOURCE Nabsys
The first safe therapy with Dr Allen's Device has once again proved its ability to…
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt…
Over 6.5 Million Glass Slides Digitized in the Last 12 Months and 15 Billion Images…
DropSafe® Sicura™ is the first and only fully passive safety needle in North America. Sicura™…